BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement f...(Riquent is being evaluated in the intern...),Health

Date:1/6/2009

Riquent is being evaluated in the international Phase 3 ASPEN trial designed to demonstrate that Riquent treatment delays the time to renal flare and reduces proteinuria in patients with lupus renal disease. The Riquent Phase 3 program is the subject of a special protocol assessment and has fast track designation from the Food and Drug Administration and Orphan Drug designation in the United States and Europe. The first and the second interim efficacy analysis are expected to occur in the first quarter of 2009 and mid- 2009, respectively. The final efficacy analysis is expected to occur in the second half of 2009. Assuming a positive outcome of the ASPEN Phase 3 trial, a New Drug Application is expected to be submitted in the first half of 2010. If approved, Riquent would be the first new drug approved specifically for lupus in more than 45 years.

BioMarin Conference Call Information

BioMarin will hold a conference call today, January 6, 2009, at 5:00 p.m. ET to discuss this announcement. This event can be accessed on the investor section of the BioMarin website at http://www.BMRN.com.

    Date: January 6, 2009
    Time: 5:00 p.m. ET
    U.S. and Canada Toll-Free Dial in #: 866.700.7477
    International Dial in #: 617.213.8840
    Participant Code: 66691013
    Replay Toll-Free Dial in #: 888-286-8010
    Replay International Dial in #: 617-801-6888
    Replay Code: 82654807

La Jolla Conference Call information

La Jolla will hold a conference call tomorrow morning, January 7, 2009, at 8:00 a.m. ET to discuss this announcement. This event can be accessed on the La Jolla website at http://www.ljpc.com. A replay of the conference call will be available later in the day of the call on La Jolla's Web site http://www.ljpc.com and
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.; La Jolla Pharmaceutical Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. BioMarin to Present at the Bear Stearns 20th Annual Healthcare Conference
2. BioMarin Provides Grant to NORD to Expand PKU Patient Support Services
3. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
4. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
5. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
6. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
7. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
8. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
9. Pfizer Closes La Jolla Campus Due to Continuing Fire Emergency
10. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference